Biopharma Daily Stock Updates - 03/08/21

$XBI $134.93 -3% 📉

Covid Updates

$CYDY -28% Announced mix data in critically ill COVID-19 patients receiving Leronlimab PRO 140. They also announced plans to file accelerated rolling review with MHRA source

Pipeline Updates

$CARA -1% NDA acceptance of Korsuva injection in hemodialysis patients with moderate-to-severe pruritus. source

$MCRB -7% Discontinues enrollment in SER-401 study in metastatic melanoma. Discontinuation due to difficulty enrolling due to COVID-19, company focusing on other pipeline assets and deprioritizes SER-401. source

$SESN +1% Submits MAA to EMA for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). source

$ANAB -34% Announced that it's phase 2 trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP), also known as POPLAR trial, failed to meet it's primary endpoints. source

$SLNO -49% Following the Type C meeting with the FDA regarding DCCR, they informed the company an additional controlled clinical trial will be necessary to support an NDA submission. source

$XENE -1% IND acceptance for a phase 2 trial of XEN1101 in major depressive disorder (MDD) set to initiate in Q2 2021. source


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.